Serum Biomarkers and Algorithm of Lung Decline in Cystic Fibrosis
Novel serum protein biomarkers and functional data analysis produce a predictive test for lung function decline.
Lung disease progression remains the leading problem in Cystic Fibrosis (CF) care and is not corrected by presently available therapies. Aggressive therapy has been shown to enhance quality of life and improve survival; however, it is impractical and expensive to aggressively treat all patients proactively without evidence of disease progression. Therefore, caregivers have depended on outcomes measures, most of which are lagging indicators, to guide treatment decisions. Novel outcome measures of lung function decline that are superior to presently used measures are needed for improving CF (and severe asthma and COPD) patient health and survival, and personalizing care.
Researchers at Cincinnati Children’s have identified leading or prognostic indicators of disease progression including: 1) measurable markers that precede disease progression and therefore help inform course of therapy, 2) accelerate CF clinical trials with rapid outcome measures for effectiveness of drug therapy in stemming disease progression, 3) the molecular fingerprints of CF disease progression in serum, and 4) provide a novel algorithm for lung function decline that is superior to the present technology.
Cystic Fibrosis, Chronic Obstructive Pulmonary Disease, Severe Asthma
Combines serum biomarkers and lung function to predict lung function decline.
More than 30K people in the US are living with CF. Approximately 1K new cases are diagnosed each year. There is no cure for the disease, and the rate of progression varies widely.
Rhonda Szczesniak, PhD, Division of Biostatistics and Epidemiology Assem Ziady, PhD; John Clancy, MD, Division of Pulmonary Medicine